Brief: Personalis And Tempus Enter Into A Strategic Collaboration To Advance Cancer Testing
28/11/2023 22:54
Nov 28 (Reuters) - Personalis Inc PSNL.O :
* PERSONALIS AND TEMPUS ENTER INTO A STRATEGIC COLLABORATION
TO
ADVANCE CANCER TESTING
* PERSONALIS INC: EXCLUSIVE ARRANGEMENT WILL EXPAND MARKET
ACCESS
TO PERSONALIS' ULTRA-SENSITIVE MRD TEST
* PERSONALIS INC-AS A PART OF DEAL, TEMPUS WILL PROVIDE UP
TO $12
MILLION TO PERSONALIS AS CERTAIN MILESTONES ARE MET
* PERSONALIS INC- AS PART OF DEAL, PERSONALIS WILL PROVIDE
WARRANTS TO TEMPUS TO PURCHASE UP TO ABOUT 9.2 MILLION SHARES OF
PERSONALIS' STOCK OVER 24 MONTHS
Source text for Eikon: ID:nBw3XXQvsa
Further company coverage: PSNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempus Holdings
See all newsBrief: Tempus Says Loan Made Available To Co For Hk$11.25 Million
Brief: Tempus Says Listing Committee Decided To Cancel Co's Listing
Brief: Personalis And Tempus Announce Expanded Collaboration
Brief: Tempus Holdings Says Company And Liquidators Entered Exclusivity Agreement With Investor
Wall Street analysts bullish on genetic testing firm Tempus AI (updated)